利福昔明治疗肠易激综合征的研究进展

Research Progress about Rixifimin for the Treatment of Irritable Bowel Syndrome

肠易激综合征(IBS)是一种常见的消化系统疾病,其特点是慢性腹痛或腹部不适,伴排便习惯的改变。目前IBS发病机制尚未明确,其中肠道炎症、菌群失调、内脏高敏感性可能起重要作用。传统治疗药物主要是对症治疗,难以缓解整体症状,且症状容易反复发作。利福昔明是口服几乎不被胃肠道吸收的广谱抗生素,几乎没有药物间的相互作用。利福昔明通过调节肠道菌群,降低内脏高敏感性,能显著改善患者总体的临床症状,不良反应轻微,没有临床相关的细菌耐药性,因此日益受到人们的关注。

Irritable bowel syndrome（ IBS） is a common digestive system disease,characterized by chronic abdominal pain or discomfort,with changes in bowel habit. The pathogenesis of IBS is not clear yet,the intestinal inflammation,dysbacteriosis,visceral hyperalgesia may play an important role. The traditional treatment is symptomatic treatment and it is difficult to alleviate the overall symptomswith easy recurrence. Rifaximin is one of the broad spectrum antibiotics,which is hard to absorb by the gastrointestinal tract,with no drug interactions. Rifaximin can significantly improve the overall clinical symptoms by regulating the intestinal flora and reducing visceral hyperalgesia. The adverse reaction is mild,and there is no clinically relevant bacterial drug resistance. Therefore,it＇s getting increasing attention.